REGULATORY

Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto

By Ken Yoshino June 12, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The pharmaceutical industry is broadening its lobbying efforts beyond the Japanese government’s annual “honebuto” policy blueprint this year, as uncertainty grows over how drug policy issues will be divided among several key strategy documents. Industry officials say the prospect of…

To read the full story

LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026
Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026

REGULATORY

Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
Ishin Urges Govt to Make Healthcare, Drug Innovation Core Growth Strategy
July 3, 2026
MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
MHLW Orders Label Revisions for Four Pediatric Antibiotics
July 2, 2026
LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

COMMENTARY

New Generic Listings Plunge, Industry Heads for a Shakeout

By Tatsuya Otsuka

The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…